# Aura Biosciences, Inc.: financial statements, quarterly

AURA · Nasdaq · CIK 1501796 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/aura.md) · [Financials](/companies/aura/financials.md) · [Filings](/companies/aura/filings.md) · [Insiders](/companies/aura/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/aura/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | [15.4](/filings/0000950170-24-125428.md) | [20.3 d](/filings/0000950170-25-043943.md) | [17.1](/filings/0000950170-25-071907.md) | [16.9](/filings/0001193125-25-179426.md) | [17.0](/filings/0001193125-25-278817.md) | [22.3 d](/filings/0001193125-26-130401.md) | [23.3](/filings/0001193125-26-216808.md) | [22.9](/filings/0001193125-26-343429.md) | [22.2](/filings/0001193125-25-278817.md) | [21.9 d](/filings/0001193125-26-130401.md) | [28.0](/filings/0001193125-26-216808.md) | [30.7](/filings/0001193125-26-343429.md) |
| Operating income | $m | [(20.5)](/filings/0000950170-24-125428.md) | [(24.8) d](/filings/0000950170-25-043943.md) | [(22.3)](/filings/0000950170-25-071907.md) | [(22.8)](/filings/0001193125-25-179426.md) | [(23.2)](/filings/0001193125-25-278817.md) | [(27.8) d](/filings/0001193125-26-130401.md) | [(29.0)](/filings/0001193125-26-216808.md) | [(28.6)](/filings/0001193125-26-343429.md) | [(27.9)](/filings/0001193125-25-278817.md) | [(27.2) d](/filings/0001193125-26-130401.md) | [(34.9)](/filings/0001193125-26-216808.md) | [(48.1)](/filings/0001193125-26-343429.md) |
| Income tax | $m | [0.0 d](/filings/0000950170-24-125428.md) | [0.1 d](/filings/0000950170-25-043943.md) | [0.0](/filings/0000950170-25-071907.md) | [0.0 d](/filings/0001193125-25-179426.md) | [0.0](/filings/0001193125-25-278817.md) | [0.0 d](/filings/0001193125-26-130401.md) | [0.0](/filings/0001193125-26-216808.md) | [0.0](/filings/0001193125-26-343429.md) | [0.0](/filings/0001193125-25-278817.md) | [0.0 d](/filings/0001193125-26-130401.md) | [0.0](/filings/0001193125-26-216808.md) | [0.0](/filings/0001193125-26-343429.md) |
| Net income | $m | [(18.5)](/filings/0000950170-24-125428.md) | [(22.1) d](/filings/0000950170-25-043943.md) | [(19.7)](/filings/0001193125-25-278817.md) | [(20.3)](/filings/0001193125-25-278817.md) | [(21.0)](/filings/0001193125-25-278817.md) | [(25.8) d](/filings/0001193125-26-130401.md) | [(27.5)](/filings/0001193125-26-343429.md) | [(27.0)](/filings/0001193125-26-343429.md) | [(26.1)](/filings/0001193125-25-278817.md) | [(25.6) d](/filings/0001193125-26-130401.md) | [(33.7)](/filings/0001193125-26-343429.md) | [(45.6)](/filings/0001193125-26-343429.md) |
| Diluted EPS | $ per share | [(0.48)](/filings/0000950170-24-125428.md) | not reported | [(0.40)](/filings/0000950170-25-071907.md) | [(0.41)](/filings/0001193125-25-179426.md) | [(0.42)](/filings/0001193125-25-278817.md) | not reported | [(0.55)](/filings/0001193125-26-216808.md) | [(0.47)](/filings/0001193125-26-343429.md) | [(0.40)](/filings/0001193125-25-278817.md) | not reported | [(0.50)](/filings/0001193125-26-216808.md) | [(0.48)](/filings/0001193125-26-343429.md) |
| Basic EPS | $ per share | [(0.48)](/filings/0000950170-24-125428.md) | not reported | [(0.40)](/filings/0000950170-25-071907.md) | [(0.41)](/filings/0001193125-25-179426.md) | [(0.42)](/filings/0001193125-25-278817.md) | not reported | [(0.55)](/filings/0001193125-26-216808.md) | [(0.47)](/filings/0001193125-26-343429.md) | [(0.40)](/filings/0001193125-25-278817.md) | not reported | [(0.50)](/filings/0001193125-26-216808.md) | [(0.48)](/filings/0001193125-26-343429.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [55.6](/filings/0000950170-24-125428.md) | [41.1](/filings/0000950170-25-043943.md) | [26.3](/filings/0000950170-25-071907.md) | [30.1](/filings/0001193125-25-179426.md) | [25.4](/filings/0001193125-25-278817.md) | [31.7](/filings/0001193125-26-130401.md) | [38.2](/filings/0001193125-26-216808.md) | [107](/filings/0001193125-26-343429.md) | [47.6](/filings/0001193125-25-278817.md) | [59.5](/filings/0001193125-26-343429.md) | [84.8](/filings/0001193125-26-216808.md) | [67.8](/filings/0001193125-26-343429.md) |
| Current assets | $m | [154](/filings/0000950170-23-062097.md) | [232](/filings/0000950170-25-043943.md) | [212](/filings/0000950170-24-056265.md) | [196](/filings/0000950170-24-093308.md) | [183](/filings/0000950170-24-125428.md) | [161](/filings/0001193125-26-130401.md) | [135](/filings/0000950170-25-071907.md) | [184](/filings/0001193125-25-179426.md) | [170](/filings/0001193125-25-278817.md) | [150](/filings/0001193125-26-343429.md) | [119](/filings/0001193125-26-216808.md) | [329](/filings/0001193125-26-343429.md) |
| Total assets | $m | [180](/filings/0000950170-23-062097.md) | [255](/filings/0000950170-25-043943.md) | [235](/filings/0000950170-24-056265.md) | [218](/filings/0000950170-24-093308.md) | [205](/filings/0000950170-24-125428.md) | [183](/filings/0001193125-26-130401.md) | [155](/filings/0000950170-25-071907.md) | [204](/filings/0001193125-25-179426.md) | [190](/filings/0001193125-25-278817.md) | [169](/filings/0001193125-26-343429.md) | [138](/filings/0001193125-26-216808.md) | [348](/filings/0001193125-26-343429.md) |
| Current liabilities | $m | [10.9](/filings/0000950170-23-062097.md) | [12.4](/filings/0000950170-25-043943.md) | [9.7](/filings/0000950170-24-056265.md) | [10.5](/filings/0000950170-24-093308.md) | [14.7](/filings/0000950170-24-125428.md) | [14.9](/filings/0001193125-26-130401.md) | [12.2](/filings/0000950170-25-071907.md) | [14.9](/filings/0001193125-25-179426.md) | [18.8](/filings/0001193125-25-278817.md) | [18.4](/filings/0001193125-26-343429.md) | [16.7](/filings/0001193125-26-216808.md) | [19.6](/filings/0001193125-26-343429.md) |
| Total liabilities | $m | [28.0](/filings/0000950170-23-062097.md) | [29.2](/filings/0000950170-25-043943.md) | [26.2](/filings/0000950170-24-056265.md) | [26.8](/filings/0000950170-24-093308.md) | [30.7](/filings/0000950170-24-125428.md) | [30.5](/filings/0001193125-26-130401.md) | [27.4](/filings/0000950170-25-071907.md) | [29.8](/filings/0001193125-25-179426.md) | [33.4](/filings/0001193125-25-278817.md) | [32.5](/filings/0001193125-26-343429.md) | [30.4](/filings/0001193125-26-216808.md) | [32.9](/filings/0001193125-26-343429.md) |
| Shareholders' equity | $m | [152](/filings/0000950170-24-125428.md) | [226](/filings/0001193125-26-130401.md) | [209](/filings/0001193125-25-278817.md) | [191](/filings/0001193125-25-278817.md) | [175](/filings/0001193125-25-278817.md) | [152](/filings/0001193125-26-343429.md) | [128](/filings/0001193125-26-343429.md) | [175](/filings/0001193125-26-343429.md) | [157](/filings/0001193125-25-278817.md) | [137](/filings/0001193125-26-343429.md) | [107](/filings/0001193125-26-343429.md) | [315](/filings/0001193125-26-343429.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(15.4) d](/filings/0000950170-24-125428.md) | [(17.4) d](/filings/0000950170-25-043943.md) | [(24.5)](/filings/0000950170-25-071907.md) | [(16.1) d](/filings/0001193125-25-179426.md) | [(15.3) d](/filings/0001193125-25-278817.md) | [(24.0) d](/filings/0001193125-26-130401.md) | [(23.4)](/filings/0001193125-26-216808.md) | [(20.8) d](/filings/0001193125-26-343429.md) | [(20.1) d](/filings/0001193125-25-278817.md) | [(20.5) d](/filings/0001193125-26-130401.md) | [(29.9)](/filings/0001193125-26-216808.md) | [(32.5) d](/filings/0001193125-26-343429.md) |
| Capital expenditure | $m | [0.1 d](/filings/0000950170-24-125428.md) | [0.3 d](/filings/0000950170-25-043943.md) | [0.1](/filings/0000950170-25-071907.md) | [0.5 d](/filings/0001193125-25-179426.md) | [0.3 d](/filings/0001193125-25-278817.md) | [0.3 d](/filings/0001193125-26-130401.md) | [0.2](/filings/0001193125-26-216808.md) | [0.0 d](/filings/0001193125-26-343429.md) | [0.0 d](/filings/0001193125-25-278817.md) | [0.2 d](/filings/0001193125-26-130401.md) | [0.1](/filings/0001193125-26-216808.md) | [0.0 d](/filings/0001193125-26-343429.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [29.3](/filings/0000950170-23-062097.md) | [37.8](/filings/0000950170-24-056265.md) | [37.9](/filings/0000950170-24-093308.md) | [38.2](/filings/0000950170-24-125428.md) | [49.5](/filings/0000950170-25-071907.md) | [49.5](/filings/0001193125-25-179426.md) | [49.7](/filings/0001193125-25-278817.md) | [50.1](/filings/0001193125-26-216808.md) | [58.0](/filings/0001193125-26-343429.md) | [65.9](/filings/0001193125-25-278817.md) | [67.4](/filings/0001193125-26-216808.md) | [94.9](/filings/0001193125-26-343429.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 103,704,809 at 2026-08-06, from the cover of the [10-Q filed 2026-08-11](/filings/0001193125-26-343429.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:41 ET. No prices; not investment advice.